Sensitive GATA1 mutation screening reliably identifies neonates with Down syndrome at risk for myeloid leukemia.

Autor: Goemans BF; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. b.f.goemans@prinsesmaximacentrum.nl., Noort S; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Department of Pediatric oncology, Sophia Children's hospital, Erasmus medical center, Rotterdam, the Netherlands., Blink M; Department of Pediatrics, Amsterdam UMC, location VUmc, Amsterdam, the Netherlands., Wang YD; Department of Cell and Molecular Biology, St. Jude Children's Research Hospital, Memphis, TN, USA., Peters STCJ; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands., van Wouwe JP; Department of Child Health, Netherlands Organization of Applied Scientific Research TNO, Leiden, the Netherlands., Kaspers G; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Pediatric Oncology, Emma Children's Hospital, Amsterdam UMC, Vrije Universiteit, Amsterdam, the Netherlands.; Dutch Childhood Oncology Group (DCOG), Utrecht, the Netherlands., de Haas V; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Dutch Childhood Oncology Group (DCOG), Utrecht, the Netherlands., Kollen WJ; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Dutch Childhood Oncology Group (DCOG), Utrecht, the Netherlands., van der Velden VHJ; Department of Immunology, Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands., Gruber TA; Department of Pediatrics, Stanford School of Medicine, Stanford, CA, USA., Zwaan CM; Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.; Department of Pediatric oncology, Sophia Children's hospital, Erasmus medical center, Rotterdam, the Netherlands.; Dutch Childhood Oncology Group (DCOG), Utrecht, the Netherlands.

Publikováno v: Leukemia [Leukemia] 2021 Aug; Vol. 35 (8), pp. 2403-2406. Date of Electronic Publication: 2021 Jan 22.